Cutaneous squamous cell carcinoma is a malignant tumour of the epidermis which reproduces the appearance of keratinising cells. In frequency terms it is the second most common tumour among malignant cutaneous neoplasias.
For patients with disease not amenable to curative intent therapy, treatment options are limited to platinum-based chemotherapy regimens and more recently to the anti-PD1 immune checkpoint inhibitor.
Erlotinib is a receptor tyrosine Kinase inhibitor, which acts on the epidermal growth factor receptor(EGFR) and produces long-lasting responses with palliative benefit and relatively low toxicity, especially in patients with activating EGFR mutation
Hereby we describe the case of a 61-year-old patient diagnosed with a squamous cell carcinoma of the lower limbs, of the keratoacanthoma type, treated successively by surgical excision, isotretinoin acid, topical imiquimod and topical 5-FU without significant response. He then was started on Erlotinib 150mg od and has been in complete remission since > 3 years, knowing that his tumour does not harbour any significant mutation.